

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	WHARTON, David Peter	Examiner:	To be determined
Serial No.	10/573,344	Group Art Unit:	3743
Filed:	March 24, 2006	Docket No.	59750-012000/US
Title:	MEDICATION HOLDER		

CERTIFICATE OF TRANSMISSION

I hereby certify that this document is being transmitted electronically to the United States Patent and Trademark Office via the EFS Web e-Filing system on March 23, 2007.


Name: Victoria King

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT [37 C.F.R. § 1.56]

MAIL STOP: AMENDMENT
Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Sir/Madam:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicant brings the references listed on the attached Forms SB-08A and SB-08B to the examiner's attention. 37 C.F.R. § 1.56. Do not construe the filing of these information disclosure statements as a representation that applicant has made a search (37 C.F.R. § 1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. We enclose copies of any cited foreign documents. Copies of the U.S. references are not enclosed.

This Information Disclosure Statement is being submitted:

- ☒ 1. Within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office action on the merits, and therefore, Applicant believes no fee is required;

- ☐ 2. After the period specified in paragraph (1) above of this section, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, whichever occurs first, and is accompanied by either:
- ☐ a. A statement that:
- (i) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months before the filing of the information disclosure statement; or
 - (ii) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months before the filing of the information disclosure statement;
- ☐ b. The fee for filing an Information Disclosure Statement under 37 C.F.R. § 1.17(p) is \$180.00.
- ☐ 3. After the period specified in paragraph (2) of this section, but on or before payment of the issue fee and is accompanied by:
- ☐ a. A statement that:
- (i) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months before the filing of the information disclosure statement; or

- (ii) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months before the filing of the information disclosure statement;

☐ b. A petition requesting consideration of the information disclosure statement; and

☐ c. The petition fee set forth in 37 C.F.R. § 1.17(i).


Applicant would appreciate the examiner initialing and signing a copy of attached Forms SB-08A and SB-08B indicating that he or she considered the information and made the information of record.

If the transmittal letter is separated from this document and the PTO determines that an extension or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 50-2638.

Authorization is hereby given to charge any fees due, or credit any overpayment of fees, to Deposit Account No. 50-2638.

Respectfully submitted,

Date: March 23, 2007


Marlan D. Walker
Reg. No. 56,928

Customer Number 33,717
GREENBERG TRAURIG, LLP
2450 Colorado Avenue, Suite 400E
Santa Monica, CA 90404
Phone: (310) 586-7700
Fax: (310) 586-7800
E-mail: laipmail@gtlaw.com